Radically improving healthspan with a novel multifactorial approach to osteoarthritis
News
APPA Phase 2b Clinical Trial on Schedule
A 225 patient Phase 2b clinical trial commenced in July 2024 in multiple centres in Denmark and in Hong Kong. The trial is focused on patients with more severe OA, which aligns with patients who reported significant reduction in pain in the Phase 2a trial. As of the end of March 2025, the trial is running on schedule with 100% of the planned number of patients enrolled in the 90-day dosing trial.
APPA is a highly differentiated oral Phase 2 clinical OA drug. With a novel mechanism of action, APPA targets the multiple signalling pathways in bone, cartilage and inflammation that are involved in OA. APPA, being an oral drug, is more convenient for long term patient use than injectables. It is being investigated for its effectiveness in bringing pain relief to multiple joints.
Headline results from the study are due late 3Q 2025.
